WEKO3
アイテム
Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy.
https://repo.qst.go.jp/records/46409
https://repo.qst.go.jp/records/46409aeb73942-80bd-4ca7-a3e4-96ee0218f1d0
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2012-10-02 | |||||
| タイトル | ||||||
| タイトル | Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Ogawa, Kazuhiko
× Ogawa, Kazuhiko× Chiba, Itaru× Morioka, Takamitsu× Yoshimi, Naoki× Murayama, Sadayuki× et.al× 森岡 孝満× 吉見 直己 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | AIM: We investigated whether hypoxia-inducible factor-1aphpa (HIF-1aphpa) expression in pretreatment biopsies of esophageal cancer is predictive of clinical outcome in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). PATIENTS AND METHODS: A total of 25 patients were reviewed. Radiotherapy was administered to total doses of 40-66.6 Gy (median: 66.6 Gy) with a single fraction of 1.8-2 Gy. Cisplatin (80 mg/m2 on day 1) and 5-fluorouracil (800 mg/m2 on days 2-6) were administered concurrently with radiotherapy, every 3-4 weeks to a total of 1-2 courses. Tissue samples from esophageal cancer were obtained from all 25 patients by biopsy before concurrent CRT, and semiquantitative analyses of HIF-1aphpa expression were performed using immunohistochemical staining. RESULTS:High HIF-1aphpa expression was observed in 11 out of 25 patients (42.7%), and HIF-1aphpa expression was significantly correlated with initial response to CRT (p=0.0027). Patients with high HIF-1aphpa expression had significantly poorer local control (LC) (5-year LC: 42.7%) than those with low expression (5-year LC: 72.5%; p=0.0322). Patients with high HIF-1aphpa expression also had significantly lower recurrence-free survival (RFS) (5-year RFS: 18.2%) compared to those with low HIF-1aphpa expression (5-year RFS: 39.8%; p=0.0009), and on multivariate analysis, HIF-1aphpa (p=0.001) and number of chemotherapy courses (p=0.010) were independent prognostic factors for RFS. CONCLUSION: HIF-1aphpa expression is significantly correlated with initial response to concurrent CRT, and is predictive of RFS for patients with esophageal cancer receiving concurrent CRT. | |||||
| 書誌情報 |
Anticancer Research 巻 31, 号 6, p. 2351-2360, 発行日 2011-06 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0250-7005 | |||||
